# SBRA earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SBRA) · [Earnings tab](https://www.lopjlb.com/stock/SBRA?tab=earnings)

Updated: 2026-08-03T08:57:10

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards, Sabra Healthcare REIT moved from a mixed outlook in Q2 2024—highlighting occupancy gains but flagging supply pressure, REVPOR slowdown, and behavioral‑health setbacks—to a more confident stance by Q3 2025, with record coverage, strong SHOP occupancy, and an expanding acquisition pipeline. Guidance was raised in Q2 2024 and again in Q2 2025, while leverage steadily improved from 5.45× to around 5.0×. Margins benefited from lower labor costs and higher occupancy, though labor‑cost volatility remains a concern. Capital deployment shifted toward senior‑housing and SHOP assets, funded largely through an ATM equity program that has been repeatedly delivered. Key fears such as Medicaid rate uncertainty and behavioral‑health occupancy volatility persisted, while earlier concerns about supply pressure and REVPOR slowdown faded from later commentary. The firm consistently emphasized disciplined growth, achieving milestones like coverage highs, dividend continuity, and a credit‑rating upgrade, while some initiatives—SNF disposition and new senior‑housing development—experienced delays. Overall, the narrative reflects a transition from early‑stage operational challenges to a phase of stable growth, disciplined capital allocation, and heightened focus on high‑margin SHOP exposure.

## Latest CallCard · Q1

Sabra Health Care REIT reports robust deal flow with $400M closed/awarded YTD, record coverage levels, expanding SHOP margins, and reaffirmed 2026 guidance while planning Q2 revisit; AI initiatives and value-based care partnerships underway.','tone': {'mgmt': 0

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Sabra Health Care REIT reports robust deal flow with $400M closed/awarded YTD, record coverage levels, expanding SHOP margins, and reaffirmed 2026 guidance while planning Q2 revisit; AI initiatives and value-based care partnerships underway.','tone': {'mgmt': 0
- **2025 Q4:** Sabra Healthcare REIT reported strong Q4 2025 results with SHOP occupancy gains, margin expansion, and a robust $240M investment pipeline; guided for ~5% normalized FFO/AFFO growth in 2026 while maintaining 5x leverage and declaring a $0.30 dividend.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Prepare
- **2025 Q3:** Sabra Health Care REIT posted solid cash NOI growth, raised its SHOP exposure target to 40% and kept guidance unchanged while noting holiday‑asset occupancy lag and a robust acquisition pipeline.
- **2025 Q2:** Sabra sees strong Q2 cash NOI growth, raised 2025 guidance and targets $500M of investments, while navigating a limited skilled‑nursing pipeline and a transition of Holiday assets.
- **2025 Q1:** Sabra reports record coverage highs, strong SHOP occupancy gains, $200M+ awarded deals, reaffirmed guidance, and leverage improvement via ATM equity.
- **2024 Q4:** Sabra delivered strong Q4 with 7% normalized AFFO growth, issued 2025 guidance for ~4% growth, sees robust acquisition pipeline but faces Medicaid cut uncertainty and competitive SNF pricing. Portfolio metrics hit highs: SHOP occupancy +80bps, EBITDARM coverage 2.09x, leverage improved to 5.27x. Div
- **2024 Q3:** Sabra Healthcare REIT reports continued operational improvement across all asset classes in Q3 2024, with rising occupancy, margins, and coverage; raised 2024 guidance midpoint; leverage declining; focused on high-quality, smaller acquisitions.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management hi
- **2024 Q2:** Sabra raised 2024 guidance as cash NOI jumped 17.7%, occupancy improved in senior housing, but faces supply pressure, REVPOR slowdown and behavioral‑health conversion setbacks.

## Theme arcs

- **Occupancy demand** (improving): Occupancy rose across senior housing, skilled nursing and SHOP, offsetting early supply‑pressure concerns
- **Margin expansion** (improving): Lower labor costs and higher occupancy drove cash‑NOI margin growth
- **Leverage management** (improving): Net‑debt/EBITDA fell from 5.45× to ~5.0×, supporting covenant comfort
- **Capital deployment via ATM equity** (stable): ATM program repeatedly delivered equity to fund acquisitions and maintain dividend
- **SHOP exposure** (new): Target raised to 40% of portfolio, with strong same‑store occupancy and RevPOR gains
- **Acquisition pipeline** (improving): Robust pipeline of awarded deals exceeding $200 M and $400 M YTD
- **Medicaid and provider‑tax uncertainty** (deteriorating): Ongoing concerns about rate changes and potential tax impacts
- **Behavioral‑health strategy** (deteriorating): Initial conversion delays led to impairments; occupancy volatility persists
- **Labor cost volatility** (stable): Current low costs could rise amid political and rightsizing pressures
- **Cap‑rate environment** (deteriorating): Tightening cap rates could compress acquisition returns

## Fear persistence

- **Supply pressure** [new]: Cited in Q2 2024 as ~10% senior‑housing increase
- **REVPOR slowdown** [new]: Mentioned in Q2 2024 as limiting revenue per occupied room
- **Behavioral‑health impairment** [recurring]: Initial conversion delays in Q2 2024 and occupancy volatility noted in Q5 2025
- **Labor cost volatility** [recurring]: Low costs in Q2 2024 could rise; political/regulatory labor unknowns in Q5 2025
- **Debt covenant proximity** [new]: Net‑debt/EBITDA near covenant threshold in Q2 2024
- **Medicaid rate uncertainty** [recurring]: Medicaid cut uncertainty in Q3 2025 and rate increase pending in Q5 2025
- **Provider tax exposure** [new]: Potential federal budget impact noted in Q5 2025
- **SHOP seasonality risk** [new]: Seasonal dip risk discussed in Q5 2025
- **Pricing pressure in Canada** [new]: Canadian senior‑housing pricing constraints in Q3 2025
- **Herd behavior in SHOP** [new]: Analyst concern of oversupply in Q3 2025

## Guidance path

2024 Q2:raised → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:maintained → 2025 Q2:raised → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SBRA`